

AMENDMENTS IN THE SPECIFICATION

Please replace the paragraph beginning at page 15, line 30 with the following amended paragraph (note that part of the text inside the first set of double brackets was underlined in the original, and as indicated by the double brackets is being deleted, not added):

–The present inventors compared Plat-E cells in its initial progress to Bosc23 cells and Phoenix-E ([[http://www.stanford.edu/group/nolan/tutorials/retpkg\\_7\\_phx\\_sys.html](http://www.stanford.edu/group/nolan/tutorials/retpkg_7_phx_sys.html)] (a tutorial of Phoenix ecotropic and amphotropic packaging lines on the web site of)] Nolan Laboratory in the Department of Molecular Pharmacology/the Department of Microbiology and Immunology in the School of Medicine at Stanford University)[()]] cells in terms of its ability or inability to produce retroviruses at a high titer with long-term stability by transient transfection. The cultivation conditions for the three packaging cell lines were as follows:

According to the manufacturer's instructions, the Bosc23 cells were proliferated in DMEM containing GPT selective reagent (Specialty Media, Lavallette, NJ, USA) supplemented with 10% fetal bovine serum. Phoenix-E cells were classified by FACS using the expression of CD8 as an index, were cultured for one week in DMEM containing hygromycin (300 µg/ml) and diphtheria toxin (1 µg/ml) supplemented with 10% fetal bovine serum, and then were transferred to ~~DEME~~ DMEM supplemented with 10% bovine fetal serum which doesn't contain hygromycin and diphtheria toxin. Plat-E cells were maintained all the time in ~~DEME~~ DMEM containing blasticidin (10 µg/ml) and puromycin (1 µg/ml) supplemented with 10% fetal bovine serum. The infection efficiency of retroviruses produced from Bosc23 diminished within 3 months and that of retroviruses produced from Phoenix-E cells diminished similarly. On the other hand, retroviruses produced from Plat-E retained an average titer of approximately  $1 \times 10^7$ /ml to NIH3T3 cells for at least 4 months under conditions of drug selective pressure and an infection efficiency of 75% or more (maximum of 99%) to BaF/3 cells when they were transfected transiently.–